Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings
DZ Xu, XY Wang, XL Shen, GZ Gong, H Ren… - Journal of …, 2013 - Elsevier
Background & Aims Even though various experimental therapeutic approaches for chronic
hepatitis B infection have been reported, few of them have been verified by clinical trials. We
have developed an antigen-antibody (HBsAg-HBIG) immunogenic complex therapeutic
vaccine candidate with alum as adjuvant (YIC), aimed at breaking immune tolerance to HBV
by modulating viral antigen processing and presentation. A double-blind, placebo-
controlled, phase II B clinical trial of YIC has been reported previously, and herein we …
hepatitis B infection have been reported, few of them have been verified by clinical trials. We
have developed an antigen-antibody (HBsAg-HBIG) immunogenic complex therapeutic
vaccine candidate with alum as adjuvant (YIC), aimed at breaking immune tolerance to HBV
by modulating viral antigen processing and presentation. A double-blind, placebo-
controlled, phase II B clinical trial of YIC has been reported previously, and herein we …